Preservative-Free Tiotropium Nebulization Solution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current COPD treatments using inhalation solutions with preservatives like benzalkonium chloride can cause adverse effects such as paradoxic bronchoconstriction and occupational asthma, and often require complex preparation and administration, leading to potential dosing errors and treatment failures.
Innovation Solution
A sterile pharmaceutical composition for inhalation via nebulization comprising 0.0005% to 0.008% w/w tiotropium or its salt, disodium EDTA, and sodium chloride, free of quaternary ammonium preservatives, with a pH range of 2.2 to 2.9, provided in a prepackaged, premeasured, and preservative-free form to simplify administration and reduce adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzalkonium chloride preservative is added to inhalation solution, then shelf life and sterility are improved, but adverse effects such as paradoxic bronchoconstriction and occupational asthma occur
Solution Approach 1:
The patent removes benzalkonium chloride preservative from the inhalation solution formulation. The solution is provided as preservative-free, single-use units that are sterile at the time of manufacture, eliminating the need for preservatives and thereby avoiding adverse effects while maintaining reliability through proper sterilization and packaging.
2Adaptability or versatility
If multiple dosage units are used for COPD treatment, then flexibility in dosing is improved, but preparation complexity and risk of dosing errors increase
Solution Approach 1:
The patent divides the treatment into separate, pre-measured single-use units. Each unit contains a specific volume of inhalation solution in a separate container, allowing flexible dosing by selecting the appropriate number of units while eliminating preparation complexity and dosing errors associated with mixing multiple units.
Solution Approach 2:
The patent performs the measurement and preparation actions in advance during manufacturing. Each single-use unit is pre-filled with the exact required volume of inhalation solution and sterilized before use, eliminating the need for complex preparation and dosing calculations at the point of administration.
3Manufacturing precision
If complex preparation instructions are provided, then accurate dosing can be achieved, but ease of operation deteriorates and treatment failure risk increases
Solution Approach 1:
The patent makes each single-use unit self-contained with pre-measured solution and clear usage instructions on the packaging. The unit is designed to be directly connected to the nebulizer without requiring complex preparation, allowing patients to administer the correct dose easily by simply following the straightforward instructions.
Data Source
AI summary
The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.